Lilly, Haya Ink Potential $1B Drug Discovery Deal to Target

Lilly, Haya Ink Potential $1B Drug Discovery Deal To Target

4 weeks from now

Sep 4, 2024  · Eli Lilly is diving further into the obesity space with a potential billion-dollar deal with Haya Therapeutics. The companies announced a collaboration Wednesday to utilize the Swiss …

biospace.com

Lilly, Haya Ink $1B Biobuck Obesity Pact To Search Dark Genome

4 weeks from now

Sep 4, 2024  · The Big Pharma has put together a deal worth up to $1 billion in biobucks to partner with Haya Therapeutics to find multiple regulatory-genome-derived RNA-based drug targets. …

fiercebiotech.com

Lilly Lays Down $1B To Be ‘first In Biology’ With Obesity Gene ...

4 weeks from now

Sep 9, 2024  · Haya’s lead candidate, HTX-001, is in discovery and is separate from the company’s plans with Lilly, according to Ounzain. The Lilly investment underscores how Big …

pharmavoice.com

Lilly Partners With Haya For LncRNA Obesity Target Deal Worth $1bn

4 weeks from now

Sep 5, 2024  · Pharma giant Eli Lilly is teaming up with Haya Therapeutics in a $1bn deal to find multiple regulatory-genome-derived RNA-based drug targets, as it eyes up new targets in …

pharmaceutical-technology.com

HAYA, Lilly Launch Up-to-$1B Metabolic Collaboration

4 weeks from now

Sep 4, 2024  · HAYA, Lilly Launch Up-to-$1B Metabolic Collaboration. Pharma giant plans to apply Swiss biotech’s RNA-guided regulatory genome platform to support preclinical drug discovery …

genengnews.com

HAYA, Lilly Launch Up-to-$1B Metabolic Collaboration

4 weeks from now

Sep 4, 2024  · Samir Ounzain, PhD, co-founder and CEO of HAYA Therapeutics. The noncoding portion that makes up 98% of the human genome is anything but “junk” to HAYA Therapeutics, …

sdbn.org

Lilly To Hunt Non-coding DNA For Obesity Drugs In $1bn Deal

4 weeks from now

6 days ago  · Swiss start-up Haya Therapeutics has formed a partnership with Eli Lilly – worth up to $1 billion – to look for new therapies for obesity in non-coding DNA. The biotech focuses on …

pharmaphorum.com

Eli Lilly And HAYA Therapeutics Enter Metabolic Condition …

4 weeks from now

Sep 6, 2024  · Eli Lilly and HAYA Therapeutics have entered into a multi-year agreement worth up $1bn to discover regulatory genome targets for obesity and related metabolic conditions. ...

pmlive.com

Haya, Lilly Target Metabolic Disorders With $1B LncRNA Pact

4 weeks from now

Sep 4, 2024  · The dark matter of long non-coding RNA (lncRNA) is shades brighter, after the signing of two major deals between biotech pioneers and big pharma in the past week. Haya …

bioworld.com

Lilly And Haya In $1bn LncRNA Obesity Deal - Synapse.patsnap.com

4 weeks from now

Sep 10, 2024  · Eli Lilly has entered into a significant partnership with Haya Therapeutics, valued at $1 billion, to identify and develop new RNA-based drug targets aimed at treating …

patsnap.com

Eli Lilly Bets Up To $1B In Haya Deal For Obesity (NYSE:LLY)

4 weeks from now

Sep 4, 2024  · Eli Lilly (NYSE:LLY) has inked a deal worth up to $1B with HAYA Therapeutics, a biotech focused on a cell information processing unit known as the dark genome, to develop …

investorshealth.com

Lilly Partners With Haya For LncRNA Obesity Target Deal Worth $1bn

4 weeks from now

Sep 7, 2024  · Pharma giant Eli Lilly is teaming up with Haya Therapeutics in a $1bn deal to find multiple regulatory-genome-derived RNA-based drug targets, as it eyes up new targets in …

borderless.net

Eli Lilly Bets Up To $1B In Haya Deal For Obesity (NYSE:LLY)

4 weeks from now

Eli Lilly (NYSE:LLY) has inked a deal worth up to $1B with HAYA Therapeutics, a biotech focused on a cell information processing unit known as the dark genome, to develop drugs for …

seekingalpha.com